Bruker(BRKR) - 2023 Q1 - Quarterly Report

On a quarterly basis, the Company reviews minority investments and equity method investments to determine if there have been any events and conditions that could indicate an impairment or other-than temporary impairment. In the three months ended March 31, 2023, the Company recognized $6.9 million of impairment charge in "Interest and other income (expense), net" in the Consolidated Statement of Operations, to write-off the costs of certain minority investments. No impairments were noted in the three months ...